BioCentury
ARTICLE | Clinical News

Biovail starts Phase III of once daily Tramadol

September 19, 2000 7:00 AM UTC

Biovail (BVF; TSE:BVF) started two 12-week, double-blind Phase III studies of a once-daily dose of tramadol to treat moderate to moderately severe pain. Tramadol is marketed as Ultram in the U.S. by J...